UK Government invests £4.5 million in GARDP to counter antibiotic resistance
- Health Secretary expected to promote the UK’s leading role in bolstering global health security and tackling antimicrobial resistance at the Indian Global Forum on Thursday
- People around the world set to benefit from extra UK investment to develop innovative treatments for drug-resistant infections which cost millions of lives every year
- £4.5 million funding package for research and development group takes total UK investment to nearly £19 million
New treatments to tackle drug-resistant infections that pose the greatest threat to global health are to be developed following a multi-million-pound investment by the UK government.
Antimicrobial resistance (AMR) – where serious infections have evolved so much that antibiotics and other current treatments are no longer effective – is a silent killer costing millions of lives across the world a year, with one in five of these deaths in children under the age of five.
The £4.5 million investment made by the government’s Global AMR Innovation Fund (GAMRIF) will support the Global Antibiotic Research and Development Partnership (GARDP) to develop new treatments for drug-resistant infections identified by the World Health Organization as the greatest threat to global health and development.
Display your AMR Technology, Product and Service
Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.